Peer Education Program
Optimizing Advanced Cancer Treatment Using Complete Genomic Profiling
Featuring Dr. Daniel Catenacci, University of Chicago
In 10 minutes, learn about the importance of complete genomic profiling for patients with advanced solid tumors. Understand the barriers to treating based on comprehensive genotyping, and what you can do to optimize first-line therapy selection based on genomic testing using FDA-approved Guardant360 CDx liquid biopsy.
The Importance of FDA Approval when Choosing Liquid Biopsy
Featuring Dr. Yousef Gaffar, Maryland Oncology
In this short, on-demand video, Dr. Gaffar discusses why FDA approval for liquid biopsy is important; the clinical and performance data required for FDA approval, and how the NILE liquid versus tissue clinical study was instrumental in the approval process for Guardant360 CDx liquid biopsy.